000			01368na a2200241 4500
999			_c14138 _d14138
003			PC14138
005			20181107112335.0
008			130622s2013 xxx||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_aBermejo Pareja, Félix _9582 _eNeurología
100			_aVillarejo Galende, Alberto _9423 _eNeurología
245	0	0	_aCalmodulin levels in blood cells as a potential biomarker of Alzheimer's disease. _h[artículo]
260			_bAlzheimers Research & Therapy, _c2013
300			_a5(6):55.
500			_aFormato Vancouver: Esteras N, Alquézar C, de la Encarnación A, Villarejo A, Bermejo-Pareja F, Martín-Requero A. Calmodulin levels in blood cells as a potential biomarker of Alzheimer's disease. Alzheimers Res Ther. 2013 Nov 7;5(6):55.
501			_aPMID: 24499616
504			_aContiene 48 referencias
520			_aThe clinical features of Alzheimer's disease (AD) overlap with a number of other dementias and conclusive diagnosis is only achieved at autopsy. Accurate in-life diagnosis requires finding biomarkers suitable for early diagnosis, as well as for discrimination from other types of dementia. Mounting evidence suggests that AD-dependent processes may also affect peripheral cells. We previously reported that calmodulin (CaM) signaling is impaired in AD lymphoblasts. Here, we address the issue as to whether the assessment of CaM levels in peripheral cells could serve as a diagnostic biomarker. Methods: A total of 165 subjects were enrolled in the study, including
710			_9267 _aServicio de Neurología-Neurofisiología
856			_uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978675/ _yAcceso libre
942			_n0 _2ddc _cART